S&P 500   3,934.38
DOW   33,476.46
QQQ   282.04
Retirement Doesn't Have to Mean Golf Courses and Fishing — It Can Be Whatever You Want It to Be.
Why Your IRA Could Crash on January 16th? (Ad)
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
Costco vs Amazon: an end of the year showdown
The 3-Stock Retirement Blueprint (Ad)
There Is Fundamental Value In Broadcom, And It Yields 3.35% 
Closing prices for crude oil, gold and other commodities
The 3-Stock Retirement Blueprint (Ad)
Discount Retailers Could Make Good Bargain Stocks
How major US stock indexes fared Friday 12/9/2022
S&P 500   3,934.38
DOW   33,476.46
QQQ   282.04
Retirement Doesn't Have to Mean Golf Courses and Fishing — It Can Be Whatever You Want It to Be.
Why Your IRA Could Crash on January 16th? (Ad)
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
Costco vs Amazon: an end of the year showdown
The 3-Stock Retirement Blueprint (Ad)
There Is Fundamental Value In Broadcom, And It Yields 3.35% 
Closing prices for crude oil, gold and other commodities
The 3-Stock Retirement Blueprint (Ad)
Discount Retailers Could Make Good Bargain Stocks
How major US stock indexes fared Friday 12/9/2022
S&P 500   3,934.38
DOW   33,476.46
QQQ   282.04
Retirement Doesn't Have to Mean Golf Courses and Fishing — It Can Be Whatever You Want It to Be.
Why Your IRA Could Crash on January 16th? (Ad)
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
Costco vs Amazon: an end of the year showdown
The 3-Stock Retirement Blueprint (Ad)
There Is Fundamental Value In Broadcom, And It Yields 3.35% 
Closing prices for crude oil, gold and other commodities
The 3-Stock Retirement Blueprint (Ad)
Discount Retailers Could Make Good Bargain Stocks
How major US stock indexes fared Friday 12/9/2022
S&P 500   3,934.38
DOW   33,476.46
QQQ   282.04
Retirement Doesn't Have to Mean Golf Courses and Fishing — It Can Be Whatever You Want It to Be.
Why Your IRA Could Crash on January 16th? (Ad)
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
Costco vs Amazon: an end of the year showdown
The 3-Stock Retirement Blueprint (Ad)
There Is Fundamental Value In Broadcom, And It Yields 3.35% 
Closing prices for crude oil, gold and other commodities
The 3-Stock Retirement Blueprint (Ad)
Discount Retailers Could Make Good Bargain Stocks
How major US stock indexes fared Friday 12/9/2022
NASDAQ:LOGC

LogicBio Therapeutics - LOGC Stock Forecast, Price & News

$2.07
0.00 (0.00%)
(As of 11/16/2022)
Add
Compare
Today's Range
$2.07
$2.07
50-Day Range
$2.01
$2.07
52-Week Range
$0.26
$3.77
Volume
N/A
Average Volume
652,526 shs
Market Capitalization
$68.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.50

LogicBio Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
20.8% Upside
$2.50 Price Target
Short Interest
Healthy
1.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.49
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.72) to ($0.77) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.44 out of 5 stars

Medical Sector

964th out of 1,034 stocks

Biological Products, Except Diagnostic Industry

166th out of 172 stocks

LOGC stock logo

About LogicBio Therapeutics (NASDAQ:LOGC) Stock

LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Receive LOGC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LogicBio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LOGC Stock News Headlines

AstraZeneca acquires local startup at 660% premium
LogicBio Therapeutics Inc
Recap: LogicBio Therapeutics Q2 Earnings
LogicBio Therapeutics Inc - Stock Quote LOGC
See More Headlines
Receive LOGC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LogicBio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LOGC Company Calendar

Last Earnings
11/15/2021
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/03/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LOGC
Fax
N/A
Employees
62
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.50
High Stock Price Forecast
$2.50
Low Stock Price Forecast
$2.50
Forecasted Upside/Downside
+20.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-40,030,000.00
Net Margins
-246.71%
Pretax Margin
-246.71%

Debt

Sales & Book Value

Annual Sales
$5.41 million
Book Value
$0.48 per share

Miscellaneous

Free Float
30,293,000
Market Cap
$68.23 million
Optionable
Not Optionable
Beta
4.61

Key Executives

  • Mr. Frederic  Chereau M.B.A.Mr. Frederic Chereau M.B.A. (Age 55)
    Pres, CEO & Director
    Comp: $793.2k
  • Dr. Mark A. Kay M.D. (Age 64)
    Ph.D., Co-Founder, Chairman of Scientific Advisory Board & Independent Director
    Comp: $107.5k
  • Dr. Daniel J. Gruskin M.D. (Age 50)
    Chief Medical Officer
    Comp: $577.48k
  • Dr. Leszek Lisowski M.B.A.
    Ph.D., Co-Founder & Member of Scientific Advisory Board
  • Dr. Adi Barzel Ph.D.
    Co-Founder
  • Mr. Joshua Blacher (Age 49)
    Interim CFO, Principal Financial Officer & Principal Accounting Officer
  • Dr. Matthias Hebben Ph.D.
    Global VP & Head of Technology Devel.
  • Dr. Mariana Nacht Ph.D. (Age 58)
    Chief Scientific Officer
  • Ms. Andrea Paul J.D. (Age 41)
    Gen. Counsel & Corp. Sec.
  • Ms. Grace Lochhead
    VP & Head of HR













LOGC Stock - Frequently Asked Questions

Should I buy or sell LogicBio Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LogicBio Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" LOGC shares.
View LOGC analyst ratings
or view top-rated stocks.

What is LogicBio Therapeutics' stock price forecast for 2023?

2 brokerages have issued 1-year price objectives for LogicBio Therapeutics' shares. Their LOGC share price forecasts range from $2.50 to $2.50. On average, they expect the company's share price to reach $2.50 in the next year. This suggests a possible upside of 20.8% from the stock's current price.
View analysts price targets for LOGC
or view top-rated stocks among Wall Street analysts.

How have LOGC shares performed in 2022?

LogicBio Therapeutics' stock was trading at $2.31 at the beginning of 2022. Since then, LOGC shares have decreased by 10.4% and is now trading at $2.07.
View the best growth stocks for 2022 here
.

When is LogicBio Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 3rd 2023.
View our LOGC earnings forecast
.

How were LogicBio Therapeutics' earnings last quarter?

LogicBio Therapeutics, Inc. (NASDAQ:LOGC) released its quarterly earnings data on Monday, November, 15th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by $0.01. The firm had revenue of $2.12 million for the quarter, compared to analyst estimates of $5.02 million. LogicBio Therapeutics had a negative trailing twelve-month return on equity of 115.29% and a negative net margin of 246.71%.

What other stocks do shareholders of LogicBio Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other LogicBio Therapeutics investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), Acceleron Pharma (XLRN), Stoke Therapeutics (STOK), Precision BioSciences (DTIL), Micron Technology (MU), Homology Medicines (FIXX) and II-VI (IIVI).

When did LogicBio Therapeutics IPO?

(LOGC) raised $77 million in an initial public offering on Friday, October 19th 2018. The company issued 5,800,000 shares at $12.50-$14.00 per share. Jefferies, Barclays and William Blair acted as the underwriters for the IPO and Chardan was co-manager.

What is LogicBio Therapeutics' stock symbol?

LogicBio Therapeutics trades on the NASDAQ under the ticker symbol "LOGC."

Who are LogicBio Therapeutics' major shareholders?

LogicBio Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (1.52%), Renaissance Technologies LLC (0.86%), Citadel Advisors LLC (0.35%) and Prudential Financial Inc. (0.30%). Insiders that own company stock include Bioscience Plc Arix, Daniel Gruskin, Frederic Chereau, Kyle Chiang and Orbimed Advisors Llc.
View institutional ownership trends
.

How do I buy shares of LogicBio Therapeutics?

Shares of LOGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is LogicBio Therapeutics' stock price today?

One share of LOGC stock can currently be purchased for approximately $2.07.

How much money does LogicBio Therapeutics make?

LogicBio Therapeutics (NASDAQ:LOGC) has a market capitalization of $68.23 million and generates $5.41 million in revenue each year. The company earns $-40,030,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis.

How can I contact LogicBio Therapeutics?

LogicBio Therapeutics' mailing address is 65 HAYDEN AVENUE 2ND FLOOR, LEXINGTON MA, 02421. The official website for the company is www.logicbio.com. The company can be reached via phone at (617) 245-0399 or via email at michael@sternir.com.

This page (NASDAQ:LOGC) was last updated on 12/10/2022 by MarketBeat.com Staff